



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

2nd May 2024

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received an Order dated 30th April 2024 from Maharashtra GST authorities, disallowing certain GST credits and raising demand on account of disputing eligibility of concessional GST rate for certain products. The relevant details to be disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	Assistant Commissioner of State Tax, GST Bhavan, Mazgaon, Mumbai, Maharashtra
2	Nature and details of the action(s) taken, initiated or order(s) passed	Order dated 30 April 2024 passed under Section 73 of CGST Act, 2017; For FY 2020-21 for Tax of Rs.2,09,70,830 along with Interest of Rs. 1,34,21,332 and Penalty of Rs. 20,97,082 aggregating to a demand of Rs. 3,64,89,244. For FY 2021-22 for Tax of Rs 2,04,78,765 along with Interest of Rs. 94,20,232 and Penalty of Rs. 20,47,877 aggregating to a demand of Rs. 3,19,46,874. For FY 2022-23 for Tax of Rs. 2,16,64,171 along with Interest of Rs. 64,99,252 and Penalty of Rs 21,66,417, aggregating to a demand of Rs.3,03,29,840.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	30 th April 2024
4	Details of violation(s) / contravention(s) committed or alleged to be committed	The officer has disallowed certain GST credit and raised GST demand on account of disputing eligibility of concessional GST rate for certain products for FY 2020-21, FY 2021-22 & FY 2022-23

5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on GSK. The Company believes that the said demand is not maintainable and will be filing an Appeal against the said Order
---	--	---

Note – The said demand Order has been received by the Company on 30 April 2024, i.e. on Tuesday evening and 01 May 2024 being state Holiday due to which, the above disclosure is being made today.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni

Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151